Innate Pharma (France)
company in Marseille, France
ISIN FR0010331421 LEI 9695002Y8420ZB8HJE29
Follow Innate Pharma (France)
Weekly email: filings, results
Revenue, last year
€20.1M
−67.4% vs prior year
Net income
−€49.5M
−553.5% vs prior year
EPS, diluted
−€0.61
−577.8% vs prior year
Operating cash flow
−€6.9M
+78.8% vs prior year
Source: ESEF annual reports · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY24 | €20.1M | −€49.5M |
| FY23 | €61.6M | −€7.6M |
| FY22 | €57.7M | −€58.1M |
| FY21 | €24.7M | −€52.8M |
| FY20 | €70.5M | −€64M |
| FY19 | €85.8M | −€20.8M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY24 | −256.3% | −245.9% |
| FY23 | −20.6% | −12.3% |
| FY22 | −99.6% | −100.7% |
| FY21 | −193.6% | −213.8% |
| FY20 | −88.1% | −90.8% |
| FY19 | −31.5% | −24.2% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY24 | −€7.3M |
| FY23 | −€32.9M |
| FY22 | −€19.7M |
| FY21 | −€59.4M |
| FY20 | −€52.7M |
| FY19 | €33.7M |
- Innate Pharma (France)
- Healthcare median
Show the numbers
| Year | Innate Pharma (France) | Healthcare median |
|---|---|---|
| FY24 | −245.9% | −47% |
| FY23 | −12.3% | −58% |
| FY22 | −100.7% | −80.4% |
| FY21 | −213.8% | −71.9% |
| FY20 | −90.8% | −62.2% |
| FY19 | −24.2% | −46.3% |